- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Apimeds partners with University of Alabama for pharmaceutical innovation | 1 | Investing.com | ||
| 25.08. | Apimeds kooperiert mit University of Alabama bei Pharma-Innovation | 1 | Investing.com Deutsch | ||
| 19.08. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.07. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | Apimeds Pharmaceuticals stärkt Management mit zwei neuen Führungskräften | - | Investing.com Deutsch | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| 15.07. | Apimeds Pharmaceuticals adds two key executives to leadership team | 3 | Investing.com | ||
| 05.06. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.05. | Apimeds Pharmaceuticals US, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| 20.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.05. | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 524 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
| 12.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 170 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen | |
| 09.05. | Apimeds Pharmaceuticals starts trading at $4 per share in line with IPO pricing | 1 | Investing.com | ||
| 09.05. | Apimeds Pharmaceuticals startet Handel bei 4 US-Dollar je Aktie gemäß Börsengang-Preis | 2 | Investing.com Deutsch | ||
| 09.05. | Inflammation drug developer Apimeds Pharmaceuticals US prices IPO at $4.00, the low end of the range | 3 | Renaissance Capital | ||
| 05.05. | IPO Roundup: American Integrity Insurance, Apimeds Pharmaceuticals and more | 1 | Seeking Alpha | ||
| 02.05. | Apimeds Pharmaceuticals US, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 15.04. | Apimeds Pharmaceuticals US, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 15.04. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,700 | -1,60 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,400 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| ARCELLX | 72,71 | +0,93 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| NUVALENT | 78,50 | -0,29 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 86,45 | +0,06 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| 89BIO | 8,520 | -1,27 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,605 | 0,00 % | Is Summit Therapeutics a Buy, Sell, or Hold Now? | ||
| EVOTEC | 5,846 | +0,62 % | Evotec Prognose gekappt: Rettet der "Priority Reset"? | Evotec hat im Juli seine Umsatzprognose überraschend gesenkt und damit Anleger verunsichert. Trotz Kostensenkungen und der geplanten Veräußerung der Produktionsanlage in Toulouse bleibt das Vertrauen... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,360 | -6,74 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| TOURMALINE BIO | 47,590 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,830 | 0,00 % | Amylyx Pharmaceuticals, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 38,590 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| AVIDITY BIOSCIENCES | 46,360 | 0,00 % | Avidity Biosciences kündigt Aktienemission im Wert von 500 Millionen US-Dollar an | ||
| TREVI THERAPEUTICS | 9,610 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,750 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
APIMEDS PHARMACEUTICALS US INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.